MARKET

CYYNF

CYYNF

Cynata Therapeut
OTCPK
0.150
NaN%
Closed 09:30 10/01 EDT
OPEN
--
PREV CLOSE
0.150
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.150
52 WEEK LOW
0.150
MARKET CAP
36.52M
P/E (TTM)
-5.6391
1D
5D
1M
3M
1Y
5Y
1D
Cynata Extends R&D Tax Incentive Loan Ahead of $1.7m Rebate
TipRanks · 1d ago
Cynata Updates Corporate Governance Framework to Strengthen Board Oversight
TipRanks · 3d ago
Cynata Releases 2025/2026 Annual Report and Confirms Corporate Structure
TipRanks · 3d ago
Cynata Adjusts 2026 Results After GvHD Trial Close-Out Accrual
TipRanks · 09/24 00:27
Cynata Options Lapse, Streamlining ASX-Listed Capital Structure
TipRanks · 09/10 22:49
Cynata narrows loss but trial setbacks and cash squeeze deepen going-concern risk
TipRanks · 08/31 00:59
Cynata Plans ASX-Quoted Share Placement to Raise Capital
TipRanks · 08/25 08:08
Cynata Slashes Costs After Key Cell Therapy Trials Miss Efficacy Targets
TipRanks · 07/30 01:17
More
About CYYNF
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.

Webull offers Cynata Therapeutics Ltd stock information, including OTCPK: CYYNF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYYNF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYYNF stock methods without spending real money on the virtual paper trading platform.